Infant deaths during a trial of a medicine that protects against respiratory syncytial virus were caused by unrelated factors ...

Widespread distribution of nirsevimab to infants with respiratory syncytial virus infection raised concerns about potential ...

The drug was 88% effective against the need for medical attention among those in their second respiratory virus season.

Some Alberta doctors are calling on the provincial government to make an injection designed to protect newborns from severe ...

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV) -- which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

The good news: In October, a new preventive medicine, the monoclonal antibody Nirsevimab, became available to babies and at-risk toddlers to help protect them from RSV (Respiratory Syncytial Virus).

As of last year, RSV vaccination with Abrysvo has been recommended for pregnant women in the United States from 32 to 36 ...

The U.S. Food and Drug Administration last year approved nirsevimab, the RSV monoclonal antibody treatment, for babies and toddlers at increased risk of severe RSV, along with three RSV vaccines ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Health Canada has called nirsevimab, a long-lasting antibody that provides protection and reduces hospitalizations by over 80 ...